Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Gleason grade progression is uncommon.

Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M.

Cancer Res. 2013 Aug 15;73(16):5163-8. doi: 10.1158/0008-5472.CAN-13-0427.

2.

Should we replace the Gleason score with the amount of high-grade prostate cancer?

Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.

Eur Urol. 2007 Apr;51(4):931-9. Epub 2006 Aug 15.

PMID:
16935413
3.

Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.

Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.

J Urol. 2001 Dec;166(6):2193-7.

PMID:
11696734
4.

Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.

Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Habuchi T, Ohyama C, Arai Y.

BJU Int. 2013 May;111(6):914-20. doi: 10.1111/j.1464-410X.2012.11658.x. Epub 2013 Jan 15.

5.

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.

BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.

6.

Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?

Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT.

J Urol. 1994 Nov;152(5 Pt 2):1843-9.

PMID:
7523732
7.

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, McLeod DG.

JAMA. 1995 Oct 25;274(16):1277-81.

PMID:
7563532
9.
10.

Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level.

McGuire BB, Helfand BT, Loeb S, Hu Q, O'Brien D, Cooper P, Yang X, Catalona WJ.

BJU Int. 2012 Jun;109(12):1764-9. doi: 10.1111/j.1464-410X.2011.10628.x. Epub 2011 Oct 21.

11.

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.

BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28.

12.

Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.

Hoedemaeker RF, Rietbergen JB, Kranse R, Schröder FH, van der Kwast TH.

J Urol. 2000 Aug;164(2):411-5.

PMID:
10893598
13.

Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy.

Guimaraes MS, Quintal MM, Meirelles LR, Magna LA, Ferreira U, Billis A.

Int Braz J Urol. 2008 Jan-Feb;34(1):23-9.

14.

Prostate-specific antigen velocity and prostate cancer gleason grade and stage.

Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.

Cancer. 2007 Apr 15;109(8):1689-95.

15.

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2003 Jan;169(1):157-63.

PMID:
12478126
16.

Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.

Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.

Br J Cancer. 2002 Sep 23;87(7):726-8.

18.

Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.

Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, Hovens CM, Corcoran NM.

BJU Int. 2013 May;111(6):921-7. doi: 10.1111/j.1464-410X.2012.11665.x. Epub 2013 Jan 25.

19.

The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome.

Pierorazio P, Desai M, McCann T, Benson M, McKiernan J.

BJU Int. 2009 Jan;103(1):38-42. doi: 10.1111/j.1464-410X.2008.07952.x. Epub 2008 Sep 3.

20.

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Epstein JI, Walsh PC, Carmichael M, Brendler CB.

JAMA. 1994 Feb 2;271(5):368-74.

PMID:
7506797
Items per page

Supplemental Content

Write to the Help Desk